EIKN Stock Analysis: Eikon Therapeutics, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 663m USD | 12M Return: -20% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.27M
Warnings
Tailwinds
No distinct edge detected
Seasonality 0.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Millbrae, California, focused on developing therapies for oncology and serious unmet medical needs. Its pipeline features specialized candidates including TLR 7/8 dual-agonists, PARP1 inhibitors for solid tumors, and WRN helicase inhibitors targeting MSI-high tumors. The company also advances next-generation androgen receptor antagonists to address resistant variants in prostate cancer.
Operating within the biotechnology sector, Eikon utilizes a business model centered on high-risk, high-reward drug discovery where success depends on navigating rigorous multi-phase clinical trials. The companys focus on brain-penetrant inhibitors addresses a significant technical challenge in oncology: the blood-brain barrier, which often limits the efficacy of standard systemic treatments.
Investors should examine the fundamental data on ValueRay to better understand how this company compares to its industry peers. Eikon was incorporated in 2019 and is positioned within the small-cap segment of the healthcare market.
- Clinical data readouts for TLR 7/8 and PARP1 inhibitor pipelines
- R&D expenditure and cash runway sustainability through 2026 IPO
- Regulatory approval milestones for MSI-high tumor and brain malignancy candidates
- Competitive landscape for next-generation androgen receptor antagonists and WRN inhibitors
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA 6.82 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -209.8m > Net Income -295.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.75 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (54.1m) vs prev 0.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -370.0 > 6 (EBIT TTM -309.7m / Interest Expense TTM 837k) |
| A: 0.57 (Total Current Assets 529.5m - Total Current Liabilities 45.1m) / Total Assets 850.8m |
| B: -1.18 (Retained Earnings -1.00b / Total Assets 850.8m) |
| C: -0.46 (EBIT TTM -309.7m / Avg Total Assets 671.0m) |
| D: 1.83 (Book Value of Equity 550.7m / Total Liabilities 300.2m) |
| Altman-Z'' = -1.28 = CCC |
As of July 08, 2026, the stock is trading at USD 11.60 with a total of 443,140 shares traded. Over the past week, the price has changed by -8.95%, over one month by +29.18%, over three months by +32.12% and over the past year by -20.00%.
Current recommended Stop Loss: 10.10 (which is 12.9% or 1.4 ATR below the current price).
Eikon Therapeutics, Common has no consensus analysts rating.
P/B = 1.2043
Revenue TTM = 0.0 USD
EBIT TTM = -309.7m USD
EBITDA TTM = -286.8m USD
Long Term Debt = 245.1m USD (estimated: total debt 254.8m - short term 9.74m)
Short Term Debt = 9.74m USD (from shortTermDebt, last quarter)
Debt = 254.8m USD (from shortLongTermDebtTotal, last quarter) (leases 254.8m already included)
Net Debt = -257.8m USD (calculated: Debt 254.8m - CCE 512.6m)
Enterprise Value = 405.4m USD (663.2m + Debt 254.8m - CCE 512.6m)
Interest Coverage Ratio = -370.0 (Ebit TTM -309.7m / Interest Expense TTM 837k)
EV/FCF = -1.26x (Enterprise Value 405.4m / FCF TTM -322.3m)
FCF Yield = -79.49% (FCF TTM -322.3m / Enterprise Value 405.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 24.2m) / Revenue TTM)
Tobins Q-Ratio = 0.48 (Enterprise Value 405.4m / Total Assets 850.8m)
Interest Expense / Debt = 0.33% (Interest Expense 837k / Debt 254.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -244.6m (EBIT -309.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.37 (Total Current Assets 529.5m / Total Current Liabilities 51.1m)
Debt / Equity = 0.46 (Debt 254.8m / totalStockholderEquity, last quarter 550.7m)
Debt / EBITDA = 0.90 (negative EBITDA) (Net Debt -257.8m / EBITDA -286.8m)
Debt / FCF = 0.80 (negative FCF - burning cash) (Net Debt -257.8m / FCF TTM -322.3m)
Total Stockholder Equity = -426.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.08% (Net Income -295.8m / Total Assets 850.8m)
RoE = 69.41% (negative equity) (Net Income TTM -295.8m / Total Stockholder Equity -426.2m)
RoCE = 171.0% (negative capital employed) (EBIT -309.7m / Capital Employed (Equity -426.2m + L.T.Debt 245.1m))
RoIC = -30.00% (negative operating profit) (NOPAT -244.6m / Invested Capital 815.5m)
WACC = 13.63% (E(663.2m)/V(918.0m) * Re(18.77%) + D(254.8m)/V(918.0m) * Rd(0.33%) * (1-Tc(0.21)))
Discount Rate = 18.77% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 81.65 | Cagr: 0.38%
[DCF] Fair Price = unknown (Cash Flow -322.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.46 | Chg30d=N/A | Revisions=+25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-1.56 | Chg30d=N/A | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=-6.35 | Chg30d=-9.37% | Revisions=-17% | GrowthEPS=+94.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-6.19 | Chg30d=-9.19% | Revisions=+0% | GrowthEPS=+2.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +10% (up=4, down=3)